Miguel A. Muniain

TL;DR: Avoidance of fluoroquinolone use in high-risk patients should be considered whenever possible in order to avoid the selection of these organisms.

TL;DR: The use of rifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampsin combinations may have had different efficacies.

TL;DR: Empirical treatment of sepsis potentially caused by E. coli may need to be reconsidered in areas where such ESBL-producing isolates are present, and empirical therapy with cephalosporins or fluoroquinolones was associated with a higher mortality rate.

TL;DR: A bundle orientated to improving adherence to evidence-based QCIs improved the management of patients with SAB and was associated with reduced mortality.

TL;DR: The epidemiology of ESBL-producing E. coli as a cause of nosocomial infection is complex and previous oxyimino-beta-lactam use, diabetes, and ultimately fatal or nonfatal underlying diseases were independent risk factors for infection or colonization with CTX-M-producing isolates, whereas previous fluoroquinolone use was associated with infection or Colonization with SHV-TEM-producing isolate.